Search In this Thesis
   Search In this Thesis  
العنوان
Single Center Clinico-Epidemiological Study Of Female Patients with Breast Cancer /
المؤلف
Ayoub, Sara Mohammed Abd Elkader .
هيئة الاعداد
باحث / Sara Mohammed Abd Elkader Ayoub
مشرف / Alaa Mohamed Maria
مشرف / Nehal Mohamed ElMashad
مشرف / Bahaa Said Ebrahim
الموضوع
Clinical Oncology.
تاريخ النشر
2022.
عدد الصفحات
p 155. :
اللغة
الإنجليزية
الدرجة
ماجستير
التخصص
علم الأورام
تاريخ الإجازة
27/9/2022
مكان الإجازة
جامعة طنطا - كلية الطب - علاج الاورام والطب النووى
الفهرس
Only 14 pages are availabe for public view

from 194

from 194

Abstract

Summary
Breast cancer is the most commonly diagnosed cancer in females and the fifth leading cause of cancer related mortality, worldwide. In Egypt, BC has the highest incidence in female cancer patients. Incidence, mortality, and survival rates of BC vary considerably among different parts of the world, which could be due to many factors such as population structure, lifestyle, genetic factors, and environment. Classification of women based on risk factors can be effective in improving risk-free methods and designing targeted breast cancer screening programs. Female breast cancer represented 28.3% of patients in our study during the period from Jan 2014 to Jan 2019. The majority of patients were from Gharbia followed by kafr el-sheikh. The median age was 51 years. Postmenopausal patients were slightly higher than premenopausal. Most cases were married. Hypertension was the most co-existing comorbid illness followed by diabetes. Positive family history of breast cancer and other malignancies was present in 11.7% of patients. Half of patients were left-sided, with 74% supra-areolar in position and 5% had multicentric lesions. Stage II was the most prevalent (66.5%). Bone metastasis was found in 77.6% of de novo MBC cases. Invasive ductal carcinoma was the most common pathological subtype and grade II was the most frequent. Intraductal component, LVI and PNI were missing in a large number of pathological reports. Most cases were HR positive (ER & PR), HER2 was positive in 14.2% and KI-67 was unknown in 42.5%. Most cases were luminal, followed by TNBC.